SR 271425

08/05/2001 - "High-performance liquid chromatographic method for the estimation of the novel investigational anti-cancer agent SR271425 and its metabolites in mouse plasma."
01/01/1999 - "Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin."
02/01/2009 - "A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors."
08/01/2008 - "Phase I dose-escalation study of the thioxanthone SR271425 administered intravenously once every 3 weeks in patients with advanced malignancies."
04/01/2007 - "Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors."

04/01/2007 - "The maximum tolerated dose of SR271425 was not reached in this trial due to early termination of the trial, not related to cardiac toxicity, following the termination of the development program by the sponsor. "

01/01/1999 - "SR271425 was highly active against IV implanted leukemias, L1210 6.3 LK and AML1498 5.3 LK. "